ZILEUTON

Post-LOE

zileuton

PharmaIN

ANDAORALTABLET, EXTENDED RELEASE

Approved

Mar 2017

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

4/8 — Partial

ZILEUTON (zileuton) by PharmaIN is 5-lipoxygenase inhibitors [moa]. Approved for 5-lipoxygenase inhibitor [epc]. First approved in 2017.

Drug data last refreshed 18h ago

Mechanism of Action

5-Lipoxygenase Inhibitors

Pharmacologic Class:

5-Lipoxygenase Inhibitor

Indications

Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.

Clinical Trials (2)

NCT02047149Phase 1Terminated

Evaluating the Safety of Zileuton (Zyflo®) in Combination With Dasatinib (Sprycel®) in Chronic Myelogenous Leukemia

Started Jan 2014

2 enrolled

Chronic Myelogenous Leukemia

NCT00070486Phase 2Completed

Carboplatin and Gemcitabine Combined With Celecoxib and/or Zileuton in Treating Patients With Advanced Non-Small Cell Lung Cancer

Started Dec 2003

140 enrolled

Lung Cancer

Company

Worked on ZILEUTON at PharmaIN? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.